Literature DB >> 12193307

Relationship between thyroid autoimmunity and Yersinia enterocolitica antibodies.

Demet Corapçioğlu1, Vedia Tonyukuk, Mehmet Kiyan, Arif E Yilmaz, Rifat Emral, Nuri Kamel, Gürbüz Erdoğan.   

Abstract

It has previously been proposed that subclinical Yersinia enterocolitica infection may play a role in autoimmune thyroid disease (AITD). In this study, we investigated the relationship between the thyroid autoantibodies and the antibodies that produced against different serotypes of Y. enterocolitica. A total of 215 subjects were included into the study (65 newly diagnosed Graves' disease [GD], 57 Hashimoto's thyroiditis [HT], 53 nontoxic diffuse goiter [NTDG], and 40 subjects for control group [CG]). Thyroid receptor antibodies (TRAb), thyroid and agglutinating antibodies against Y. enterocolitica serotype O:3, O:5, O:8, O:9 were measured in the blood samples. The highest incidence of Y. enterocolitica antibody positivity was measured in GD (53.8% for O:3, 29.2% for O:5, 44.6% for O:8, and 40% for O:9) and followed by HT. In patients with GD, TRAb levels were also higher than in patients with HT, NTDG, and CG. There was no difference between NTDG and CG in respect to the titer levels and the positivity of both TRAb and Y. enterocolitica antibodies. There was also a weak linear correlation between TRAb level and the titer of antibodies against Y. enterocolitica antigens. It can be concluded that Y. enterocolitica infection may play a role in etiology of GD in Turkey.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12193307     DOI: 10.1089/105072502320288483

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  15 in total

Review 1.  Relapse prediction in Graves´ disease: Towards mathematical modeling of clinical, immune and genetic markers.

Authors:  Christoph Langenstein; Diana Schork; Klaus Badenhoop; Eva Herrmann
Journal:  Rev Endocr Metab Disord       Date:  2016-12       Impact factor: 6.514

Review 2.  Hepatitis C and interferon induced thyroiditis.

Authors:  Yaron Tomer
Journal:  J Autoimmun       Date:  2010-05       Impact factor: 7.094

3.  No causal relationship between Yersinia enterocolitica infection and autoimmune thyroid disease: evidence from a prospective study.

Authors:  G Effraimidis; J G P Tijssen; T G A Strieder; W M Wiersinga
Journal:  Clin Exp Immunol       Date:  2011-04-13       Impact factor: 4.330

4.  Yersinia enterocolitica infection does not confer an increased risk of thyroid antibodies: evidence from a Danish twin study.

Authors:  P S Hansen; B E Wenzel; T H Brix; L Hegedüs
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

Review 5.  Fecal microbiota transplantation broadening its application beyond intestinal disorders.

Authors:  Meng-Que Xu; Hai-Long Cao; Wei-Qiang Wang; Shan Wang; Xiao-Cang Cao; Fang Yan; Bang-Mao Wang
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

Review 6.  Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity.

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Endocr Rev       Date:  2013-12-04       Impact factor: 19.871

7.  Increased prevalence of antibodies to enteropathogenic Yersinia enterocolitica virulence proteins in relatives of patients with autoimmune thyroid disease.

Authors:  T G A Strieder; B E Wenzel; M F Prummel; J G P Tijssen; W M Wiersinga
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

Review 8.  Thyroid nodules and thyroid autoimmunity in the context of environmental pollution.

Authors:  Salvatore Benvenga; Alessandro Antonelli; Roberto Vita
Journal:  Rev Endocr Metab Disord       Date:  2015-12       Impact factor: 6.514

9.  The etiology of autoimmune thyroid disease: a story of genes and environment.

Authors:  Yaron Tomer; Amanda Huber
Journal:  J Autoimmun       Date:  2009 May-Jun       Impact factor: 7.094

Review 10.  Fecal Microbiota Transplantation and Its Usage in Neuropsychiatric Disorders.

Authors:  Alper Evrensel; Mehmet Emin Ceylan
Journal:  Clin Psychopharmacol Neurosci       Date:  2016-08-31       Impact factor: 2.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.